Literature DB >> 22585603

AKT as locus of cancer angiogenic robustness and fragility.

Ziv Radisavljevic1.   

Abstract

Angiogenesis get full robustness in metastatic cancer, relapsed leukemia or lymphoma when complex positive feedback loop signaling systems become integrative. A cancer hypoxic microenvironment generates positive loops inducing formation of the vascular functional shunts. AKT is an upstream angiogenic locus of integrative robustness and fragility activated by the positive loops. AKT controls two downstream nodes the mTOR and NOS in nodal organization of the signaling genes. AKT phosphorylation is regulated by a balance of an oxidant/antioxidant. Targeting AKT locus represents new principle to control integrative angiogenic robustness by the locus chemotherapy.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22585603     DOI: 10.1002/jcp.24115

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

1.  IL-8 induces the epithelial-mesenchymal transition of renal cell carcinoma cells through the activation of AKT signaling.

Authors:  Nan Zhou; Fuding Lu; Cheng Liu; Kewei Xu; Jian Huang; Dexin Yu; Liangkuan Bi
Journal:  Oncol Lett       Date:  2016-07-21       Impact factor: 2.967

2.  AKT plays a crucial role in gastric cancer.

Authors:  Takamitsu Sasaki; Yuichi Yamashita; Hiroki Kuniyasu
Journal:  Oncol Lett       Date:  2015-05-25       Impact factor: 2.967

3.  Selective TBK1/IKKi dual inhibitors with anticancer potency.

Authors:  Jijia Li; Jingjia Huang; Ji-Hak Jeong; Sun-Jin Park; Rui Wei; Jieying Peng; Zhiyong Luo; Yen Ting Chen; Yangbo Feng; Jun-Li Luo
Journal:  Int J Cancer       Date:  2013-10-21       Impact factor: 7.396

4.  Quinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathway.

Authors:  Zeng Li; Bin Wang; Liang Tang; Shuangsheng Chen; Jun Li
Journal:  Iran J Basic Med Sci       Date:  2016-04       Impact factor: 2.699

5.  Plumbagin restrains hepatocellular carcinoma angiogenesis by suppressing the migration and invasion of tumor-derived vascular endothelial cells.

Authors:  YanFei Wei; Qi Yang; Yuan Zhang; TieJian Zhao; XueMei Liu; Jing Zhong; Jing Ma; YongXin Chen; Chuan Zhao; JunXuan Li
Journal:  Oncotarget       Date:  2017-02-28

6.  Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model.

Authors:  Kodappully Sivaraman Siveen; Kwang Seok Ahn; Tina H Ong; Muthu K Shanmugam; Feng Li; Wei Ney Yap; Alan Prem Kumar; Chee Wai Fong; Vinay Tergaonkar; Kam M Hui; Gautam Sethi
Journal:  Oncotarget       Date:  2014-04-15

7.  Upregulation of Akt/NF-κB-regulated inflammation and Akt/Bad-related apoptosis signaling pathway involved in hepatic carcinoma process: suppression by carnosic acid nanoparticle.

Authors:  Bo Tang; Fang Tang; Zhenran Wang; Guangying Qi; Xingsi Liang; Bo Li; Shengguang Yuan; Jie Liu; Shuiping Yu; Songqing He
Journal:  Int J Nanomedicine       Date:  2016-11-30

8.  Indole hydrazide compound ZJQ-24 inhibits angiogenesis and induces apoptosis cell death through abrogation of AKT/mTOR pathway in hepatocellular carcinoma.

Authors:  Jing Liu; Ying Liu; Jianqiang Zhang; Dan Liu; Yafeng Bao; Tianxing Chen; Tao Tang; Jun Lin; Ying Luo; Yi Jin; Jihong Zhang
Journal:  Cell Death Dis       Date:  2020-10-28       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.